Payment overview · 2025
General Payments
$1,554.57
66 reported records · 11 companies
Healthcare provider profile · identity verified
Courage A Atekha, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · STATESBORO, GA · NPI 1124119219
Verified facts
What the public records show
CMS Open Payments records show Courage A Atekha, M.D. received $1,554.57 in general payments during 2025 across 66 reported records.
Ardelyx, Inc. accounted for 19.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Rayaldee.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 324 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Lokelma by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 293 claims for Jardiance by this doctor in 2024.
OPKO Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RAYALDEE as an associated drug or biological on 5435 records involving 1739 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Rayaldee by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $294.94 | 19.0% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $228.15 | 14.7% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $205.99 | 13.2% | 8 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $172.87 | 11.1% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $171.18 | 11.0% | 9 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $160.95 | 10.3% | 6 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $89.68 | 5.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $83.69 | 5.4% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $70.51 | 4.5% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $60.46 | 3.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.15 | 1.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,460.85 | 60 |
| Education | $93.72 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $294.94 | 10 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $228.15 | 7 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $205.99 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $171.18 | 9 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $160.95 | 6 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $89.68 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $83.69 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $70.51 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $60.46 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| Filspari Normalized: filspari |
Drug | Travere Therapeutics, Inc. | $4.04 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 324 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 293 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 184 | exact normalized | Medicare Part D |
| RAYALDEE rayaldee |
2025 | Rayaldee | 2024 | 244 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
324 | 74 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
55 | 12 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
184 | 33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
293 | 60 |
| OPKO Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | RAYALDEE open payments reported associated product |
CMS Open Payments — General Payments 5435 supporting records · 1739 recipient NPIs · example record 1222072234 |
Rayaldee · 2024 Exact normalized brand match · 1 Part D row |
244 | 37 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 469 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 350 | 95 |
| Sevelamer Carbonate | Sevelamer Carbonate | 345 | 86 |
| Calcitriol | Calcitriol | 327 | 79 |
| Farxiga | Dapagliflozin Propanediol | 324 | 74 |
| Furosemide | Furosemide | 315 | 80 |
| Jardiance | Empagliflozin | 293 | 60 |
| Carvedilol | Carvedilol | 263 | 73 |
| Rayaldee | Calcifediol | 244 | 37 |
| Atorvastatin Calcium | Atorvastatin Calcium | 223 | 62 |
| Potassium Chloride | Potassium Chloride | 214 | 49 |
| Hydralazine Hcl | Hydralazine Hcl | 209 | 47 |
| Kerendia | Finerenone | 184 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 167 | 42 |
| Allopurinol | Allopurinol | 156 | 32 |
| Calcium Acetate | Calcium Acetate | 128 | 41 |
| Gabapentin | Gabapentin | 122 | 30 |
| Famotidine | Famotidine | 100 | 26 |
| Spironolactone | Spironolactone | 98 | 24 |
| Nifedipine Er | Nifedipine | 93 | 23 |
| Lisinopril | Lisinopril | 89 | 28 |
| Ezetimibe | Ezetimibe | 85 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 83 | 26 |
| Torsemide | Torsemide | 83 | 18 |
| Metformin Hcl | Metformin Hcl | 75 | 18 |
| Simvastatin | Simvastatin | 66 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 63 | 54 |
| Glipizide | Glipizide | 63 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 63 | 13 |
| Tramadol Hcl | Tramadol Hcl | 61 | 33 |
| Clonidine Hcl | Clonidine Hcl | 60 | 14 |
| Lokelma | Sodium Zirconium Cyclosilicate | 55 | 12 |
| Midodrine Hcl | Midodrine Hcl | 53 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 14 |
| Omeprazole | Omeprazole | 50 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 47 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | 12 |
| Januvia | Sitagliptin Phosphate | 45 | 12 |
| Prednisone | Prednisone | 45 | 19 |
| Veltassa | Patiromer Calcium Sorbitex | 41 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 38 | suppressed |
| Chlorthalidone | Chlorthalidone | 37 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 37 | suppressed |
| Auryxia | Ferric Citrate | 35 | suppressed |
| Metolazone | Metolazone | 35 | 13 |
| Levothyroxine Sodium | Levothyroxine Sodium | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Telmisartan | Telmisartan | 33 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 32 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 15 |
| Xphozah | Tenapanor Hcl | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Fluconazole | Fluconazole | 30 | 22 |
| Prosol | Parenteral Amino Acid 20% No.1 | 30 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 30 | suppressed |
| Eliquis | Apixaban | 29 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 27 | suppressed |
| Finasteride | Finasteride | 27 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Febuxostat | Febuxostat | 26 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Eplerenone | Eplerenone | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Carisoprodol | Carisoprodol | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Minoxidil | Minoxidil | 18 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | 15 |
| Gentamicin Sulfate | Gentamicin Sulfate | 17 | suppressed |
| Lactulose | Lactulose | 17 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 16 | suppressed |
| Novolin R | Insulin Regular, Human | 16 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Colchicine | Colchicine | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 11 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Sulindac | Sulindac | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,554.57 · 66 records | Ardelyx, Inc. | AREXVY, FARXIGA, Filspari, IBSRELA, JARDIANCE, JYNARQUE, KRYSTEXXA, Kerendia, RAYALDEE, SHINGRIX, TARPEYO, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error